|Publication number||WO2005050563 A2|
|Publication date||2 Jun 2005|
|Filing date||17 Nov 2004|
|Priority date||17 Nov 2003|
|Also published as||US7483554, US20050165290, US20090262993, WO2005050563A3|
|Publication number||PCT/2004/38536, PCT/US/2004/038536, PCT/US/2004/38536, PCT/US/4/038536, PCT/US/4/38536, PCT/US2004/038536, PCT/US2004/38536, PCT/US2004038536, PCT/US200438536, PCT/US4/038536, PCT/US4/38536, PCT/US4038536, PCT/US438536, WO 2005/050563 A2, WO 2005050563 A2, WO 2005050563A2, WO-A2-2005050563, WO2005/050563A2, WO2005050563 A2, WO2005050563A2|
|Inventors||Angeliki Kotsianti, Olivier Saidi, Mikhail Teverovskiy|
|Applicant||Aureon Biosciences Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (5), Non-Patent Citations (3), Referenced by (7), Classifications (21), Legal Events (6)|
|External Links: Patentscope, Espacenet|
PATHOLOGICAL TISSUE MAPPING
Field of the Invention This invention relates to molecular biology, histology, and clinical diagnostics. Clinical, micro-anatomic and molecular profiles of disease are integrated to create a system for tissue analysis which, in a preferred embodiment, comprises a pathological mapping of a tissue image to deteπnine a pathological status or condition of the tissue in the image.
B ackground of the Invention Pathology is the medical science and specialty practice that deals with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions. This generally includes analysis of the structural and functional changes that result from diseases. To determine the causes of a disease, a pathologist may study: how various internal and external injuries affect cells and tissues, how a disease progresses (pathogenesis), and how a disease manifests in a tissue (i.e., its clinical expression and the lesions produced). In other words, pathology provides a scientific foundation for clinical medicine and serves as a bridge between the basic sciences and patient care. Accordingly, accurate and repeatable quantitative analysis of tissue is important to characterize a disease and evaluate effects that new therapies might have. To date, little if any reliable structural information exists at the tissue level (e.g., 1-1000 microns, in the range of microscopic to mesoscopic). It is believed that if reliable, multi-dimensional structural tissue information (including, for example, clinical, molecular and genetic information) existed in readily accessible databases. Such information would enhance and accelerate new advances in tissue engineering, drug design, gene discovery, proteomics, and genomics research. In order to facilitate the study and diagnosis of disease, investigators have developed a variety of systems and methods. Generally, prior art methods and systems relating to the study of disease are slow, difficult and prone to error. Accordingly, there exists a need for a system and/or method to quickly, efficiently, and/or automatically quantify tissue for determining a condition of a tissue.
SUMMARY OF THE INVENTION The present invention presents methods and systems for processing and analyzing a tissue image(s), and moreover, with regard to some embodiments of the invention, for automating object/feature extraction from tissue and/or determining quantitative definition of tissue features. Embodiments of the present invention produce a pathological tissue map (PTM) of the tissue, which comprises a modified version of an image of the tissue. The PTM classifies objects of the tissue into visible indicators which may be analyzed quickly by a user (e.g., pathologist) and/or an algorithm, to more quickly determine a tissue condition (e.g., normal versus abnormal). For example, a PTM may be generated by quantifying a variety of , micro-anatomic and/or molecular data and associating a color grade with a range for that particular data. Accordingly, the data may be rendered in a format where areas of abnormality are identified in a specific color (red for example), which may be easily identifiable to a viewer (e.g., pathologists, scientists or physicians). In one embodiment of the invention, an automated tissue processing system is disclosed, for advanced tissue image classification of (for example) hematoxylin and eosin (H&E)-stained tissue sections. Using such a system, tissue images may be segmented then analyzed. Furthermore, using neural network or support vector regression ("SVR"), the segmented images may be used to train a biostatistical model to determine tissue condition (e.g., normal versus abnormal). In particular, such a system may facilitate distinguishing and visualizing an object in a tissue image using predetermined criteria. When an object is found, boundaries of the object may be constructed using (for example) modified object extraction algorithms used in the art. Criteria for locating tissue objects may include, for example, object color, color intensity, object morphology (including material composition), object size and shape (e.g., dimensions, round, oval, etc.), arrangement of objects, or any combination thereof. For example, with regard to color, a tissue may be stained to highlight certain objects. To detect tissue objects in an image, existing mathematical feature detection algorithms may be used, or modified versions thereof, such as those available with the Cellenger software product marketed by Definiens A.G. Such algorithms may include, for example, dilation (adding pixels to the boundary of an object), erosion (removing pixels on the object boundaries), and thresholding. In addition, the detection of background intensity is useful for object determination and is required in some feature extraction algorithms. One can also apply one or more morphological filters to enhance certain objects and suppress others. Such enhancements may change the shape of an object contained within an image. Morphological filters are preferably used prior to applying character/shape recognition algorithms since these filters can highlight the contour of objects which aid the recognition. For example, a morphological filter may be used to enhance certain objects of a particular size and the dilation and/or erosion algorithms may be used to bring out the enhanced objects. Embodiments of the invention may further include quantitative determination of object geometry. One or more found objects may be quantified (e.g., measured), and a modified tissue image established with visual indicators indicating the quantified objects. The modified image represents the PTM for pathological analysis. Still other embodiments of the present invention are directed to databases, which may be used in conjunction with other embodiments of the invention. Specifically, such databases may include characterization data and/or associated images ("tissue information") representative of a tissue population, and/or an automated method to create such database and use of the database for classification and evaluation of tissue specimens. For example, samples of normal tissue specimens obtained from a subset of a population of subjects with shared characteristics may be profiled (e.g., objects extracted and classified as normal) in order to generate a plurality of structural indices that correspond to statistically significant representations of tissue associated with the population. The database may also include information from profiled tissue images from samples of specimens of a particular tissue obtained from a subset of a population with respect to certain structural or other indicia, that correspond to a particular clinical condition associated with that tissue. Such information may be used to provide a comparison with information obtained from additional specimens of the tissue, including specimens which may have been previously profiled by other means or for other purposes. Indicia may include at least one of cell density, matrix density, blood vessel density, layer thickness or geometry, and the like. Embodiments of the invention maybe used to identify a toxic effect or response, immunological reactions, morphological lesions caused by, for example, hepatitis (acute, subacute and chronic), cholestasis (with and without inflammation or necrosis), fibrosis, , granulomatous hepatitis, steatosis (macro and microvesicular), vascular lesions, and hepatic tumors. Further yet, embodiments of the invention may be used to characterize pathological objects, for example, Kupffer cell hyperplasia, cholangitis, cholangiolitis, necrotizing angitis, sinusoidal dilatation, hepatoportal sclerosis and venous thromboses.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 A is a general block diagram representing a process flow for pathological tissue mapping according to some of the embodiments of the present invention. Fig. IB is a block diagram representing a specific process flow for'pathological tissue mapping according to one embodiment of the present invention. Fig. 1C is a representative system for carrying out method embodiments for the present invention. Fig. 2 is a block diagram representing a process flow for image segmentation according to some embodiments of the present invention. Fig. 3 A is an original image of normal liver tissue. Fig. 3B is a segmented image of the normal liver tissue of Fig. 3 A, illustrating hepatic nuclei, kupffer nuclei, sinusoids and fat content. Fig. 3 C is an original image of abnormal liver tissue. Fig. 3D is a segmented image of the abnormal liver tissue of Fig. 3C, illustrating hepatic nuclei, kupffer nuclei, sinusoids and fat content. Fig. 4A is an original tissue image of a bile duct. Fig. 4B is a segmented image of the bile duct of Fig. 4 A, illustrating bile duct lumen, epithelial nuclei, hepatic artery lumen, and hepatic nuclei. Fig. 5 A is an original tissue image of a hepatic vein. Fig. 5B is a segmented image of the hepatic vein of Fig. 5 A, illustrating hepatic vein lumen, hepatic vein wall and hepatic nuclei. Fig. 6 A is an original tissue image of a hepatic artery. Fig. 6B is a segmented image of the hepatic artery of Fig. 6 A, illustrating hepatic artery, red blood cells and hepatic nuclei. Fig. 7A is an original image of a hepatocyte. Fig. 7B is a segmented image of the hepatocyte of Fig. 7 A. Fig. 8 A is an H&E stained tissue image of normal liver tissue. Fig. 8B is a segmented image of the stained image of Fig. 8 A. Fig. 8C is a pathological tissue map of the original image of Fig. 8 A and segmented image of Fig. 8B. Fig. 9A is an H&E stained tissue image of abnormal liver tissue. Fig. 9B is a segmented image of the stained image of Fig. 8 A. Fig. 9C is a pathological tissue map of the original image of Fig. 8 A and segmented image of Fig. 8B. Fig. 10 illustrates nests of polygonal cells with pink cytoplasm and distinct cell borders in squamous cell lung carcinoma. Fig. 11 is an image of columnar cells with reference to bronchioloalveolar lung carcinoma. Fig. 12 is an image showing small dark blue cells with minimal cytoplasm packed together in sheets of oat cell disease. Fig. 13 is an image of tubular structures of malignant glandular neoplasia (colon cancer). Fig. 14 is an image of goblet cells (colon cancer). Fig. 15 illustrates a pathological staging of bladder cancer based on invasiveness. Fig. 16 is an image of papillary projections for determining transitional cell carcinoma of the urothelium. Fig. 17 is an image of neoplastic cells having uniform oval nuclei, abundant cytoplasm, and are arranged in ribbons of tissue supported by delicate vascular cores or "stalks". Fig. 18, a photomicrograph of carcinoma in situ in the bladder.
DETAILED DESCRIPTION OF THE EMBODIMENTS Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill m the art to which this invention belongs. Although methods, systems and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods, systems and materials are described below. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Moreover, although most of the embodiments of the present invention will be described with reference to a liver tissue analysis example, it is meant as an example only and not intended to be limiting. Some embodiments of the present invention relates to an automated measurement and analysis system to quantitatively evaluate one or more tissue features/objects. The tissue specimens that can be analyzed by the present invention may include any tissue of any organ system, including, for example, liver, kidney, bile duct, gastrointestinal tract, lymphatic vessel, bronchia, blood vessels, cardiac, and nerve tissues. The images are processed to produce a modified image of a tissue image with visual markers for indicating the pathology of the tissue (the PTM), that can more easily be analyzed by a diagnosis algorithm or pathologist. Once tissue specimens have been prepared, generally, the process for producing a PTM includes: acquiring an image of the tissue specimen; segmenting the image, classifying one or more objects, quantifying one or more objects, creating a modified image with visual indicators for the quantified objects; and pathologically classifying the tissue. A general overview of these steps is shown in Fig. 1A, with a more specific flow illustrated in Fig. IB. Fig. 1C is a block diagram of a system for carrying out one or another of the method embodiments according to the present invention. As shown, a computer having an input module which may comprise a keyboard, ports (e.g., USB, parallel, SCSI, serial, and the like), a computing module (i.e., a computer workstation; a processor), a display and a printer. The ports may be used to connect image acquisition equipment (e.g., microscope having digital camera/CCD/CMOS device), as well as connecting external data storage devices (e.g., CD-ROM/RW; hard-drives, DVD, etc.). The system may be part of a larger network, and may communicate with such network either via wireless or wired (e.g., Ethernet) connection. Tissue images may be obtained in any number of ways familiar to those of skill in the art. For example, X-ray images (including CAT scan images) and MRI images may be used, digitized to be input into a computer system. Particular preferred embodiments of the invention may obtain images by taking a photograph (preferably digital, but may be a traditional photo which is later digitized) of a magnified section of a tissue slide (e.g., a cross-sectional slice of tissue) on a microscope. Segmenting tissue images may include one or more of: preprocessing images to correct color variations; location of tissue histopatholic objects; and classifying the found objects. A general overview of the segmentation process is illustrated in Fig. 2. Initially, images may be pre-processed to standardize color variations from image to image (e.g., when using H&E stained tissue) of a tissue, using, for example, color
(histogram) normalization. Images of tissues stained under different conditions and time may have color variations from image to image which may impair object classification in the image. Accordingly, histogram equalization may be used to bring image colors into close ranges. To standardize the color variations in a set of images of a particular tissue, one tissue image may be selected as the representative image, and then the histogram for each of the tissue images remaining in the set may be adjusted so that each matches the histogram of the representative image. Alternatively, the histograms of several images may be used to derive an average (for example) histogram for the image set. After pre-processing, tissue histopatholic objects are located. Each object may be a basic object or a composite object. Basic objects may include, for example, fundamental objects of tissue, including cell components (e.g., nuclei, sinusoids, fat and fat vacuoles, cytoplasm). Composite objects may be more complex than basic objects and are typically constructed from basic objects. Examples of composite objects include: cells (e.g., hepatocytes) and vascular tissues (e.g., bile duct, veins, arteries). For example, a composite object may represent an entire cell, made up of basic objects including nuclei and cytoplasm (for example). Each cell may be "grown" using a cell growing algorithm, where a specific object ("seed") for cell formation (e.g., hepatic nuclei for the hepatocytes) is used as the basis for forming the cell, and then other objects are added to it. Image segmentation may be based on object oriented image analysis, where an image (preferably non-equalized) is partitioned into homogenous groups with respect to color and shape of adjacent areas (i.e., image objects). The image information can be represented in different scale depending on the average size of the objects. Accordingly, using spectral and shape characteristics, image objects may then be referred to as instances of the tissue histopathological objects. Besides using spectral and shape criteria to find objects, spatial relations between objects may also be taken into consideration to find objects. For example, sinusoids may be identified as elongated image objects containing red blood cells located within a range of known distances from Kupffer cells. Hepatocytes, tissue structure composed of cytoplasm, fat, fat vacuoles and hepatic nuclei bordering along sinusoids, may be found using hepatic nuclei objects as "seeds", and "growing" the hepatocyte sequentially by adding surrounding image objects until it reaches a sinusoid object. A region growing algorithm may be used for such cell formation. To further enhance and automate the analysis process, tools commonly used with computer-aided-design (CAD) software may be used with the image-processing embodiments of the invention to aid in extracting objects from tissue images. The CAD tools offer the ability to pick points and group them, fit polynomial curves or splines to groups of points, and the ability to merge curve segments in an ordered fashion so they bound regions of interest. Such tools may be used to correct objects which have been incorrectly extracted. After objects (basic and/or composite) have been found, the found objects may then be classified. For example, with nuclei classification, image objects may be classified as "nuclei" versus "non-nuclei" class objects using, for example, spectral and shape characteristics. The nuclei objects may be further sub-divided in two categories: "epithelial nuclei" and "inflammatory cells", for example. Moreover, with regard to liver tissue analysis, color intensity, shape and/or size thresholds may be used to classify the "epithelial nuclei" objects as "hepatic nuclei" and "Kupffer cells" nuclei objects. It is worth noting that sometimes a single nucleolus object is actually a plurality of real nuclei merged together. In such a situation, specialized morphological operations may defuse the nuclei objects into respective nuclei. After nuclei objects have been classified, white spaces of the image may also be classified. White spaces are objects which are non-nuclei objects, and may be determined based on an intensity threshold (for example) of the non-nuclei objects. Objects such as red-blood cells, fat, fat vacuoles and sinusoids objects may then be derived from the white space. Once objects have been classified, one or more objects, as well as one or more parameters of objects (a basic object may, in some embodiments, represent a parameter of a composite object, for example) maybe quantified to analyze the tissue to determine a pathological condition of the tissue (e.g., normal versus abnormal) via a PTM. h some embodiments, quantification relates to the determination of a value for a specific object/parameter relative to a granularity unit of the image. A granularity unit may comprise another object, basic or composite (preferably composite), the tissue image itself, or a specific area of the image, color, color intensity, size, shape, and the like. The value of the specific object/parameter may be a quantity, a color, color intensity, a size, an area, or a shape. The value may also be a ratio; for example, the ratio may be the area of the specific object relative to the area of the granularity unit. For example, in liver cells, a cell object (e.g., nucleus, fat) can be quantified by establishing a ratio of the area of the cell object to that of the area of the cell.
Specifically, for each cell in the image, the cell area is measured (Aj), the object area (Oj) is measured, and the ratio of O; / Aj is determined. A ratio interval may then be set based on the range of ratios found in image. The result of quantification may be organized into a number of "bins", where each bin is associated with a particular visual indicator (e.g., color). Representative pixels of the quantified objects in a modified image of the original tissue image are then marked with indicators (e.g., colorized) with the corresponding bin indicator to produce the PTM. Accordingly, a pathologist can view the PTM to easily determine the state of the tissue for a particular object quantification. The visual indicator may comprise a symbol, a color, a letter, a number and the like. Any visual detail to display attention to the quantified object in the modified image.
Liver Toxicology For liver toxicology (for example) analysis, such quantification may be the analysis of hepatocytes (granularity unit) based on the fat content (fat molecule: quantified object) of the cell (a fat PTM) or hepatic nuclei (nuclei PTM). Fat accumulating in the liver is mainly in the form of triglycerides and fatty acids, and is also present in small amounts in the form of cholesterol, cholesterol ester and phospholipids. Fat accumulation in the liver may be designated pathologically as "fatty degeneration of the liver", and is also referred to as "fatty change", "fat infiltration", "fat metamorphosis" and "steatosis of the liver". Fatty liver is observed in a multitude of conditions such as: obesity, hyperalimentation (hypernutrition), alcoholic liver disease, diabetes mellitus, congestive heart failure, drug intoxication, pregnancy, Rey's syndrome, malnutrition (Kwashiorkor), chronic hepatitis and cirrhosis of different etiology. Figs. 3A-6B represent example segmented images of original tissue images. For hepatic fat, the fat content generally ranges from 0 (a cell free of fat) to 1 (a cell replaced by fat), with varying degrees of fat therebetween (e.g., 0.1, 0.2, etc.). The range of fat content may be divided into the ratio interval - into a number of bins, each of which corresponds to a color (or color intensity/shade), in a graded range. Each hepatocyte cell object is then assigned to a particular bin based on its quantified fat content. The pixels in a modified image of the original tissue image corresponding to each hepatocyte cell object is then colorized with the corresponding bin color to establish the PTM of the tissue. The completed PTM may then be output on a LCD/CRT display or output to a printer (and/or database) for review. In general, in many quantification, the ratio interval may be set up to vary from 0 to 1, but sometimes the bins derived from the interval [0, 1] do not have enough resolution; almost all ratios can fall into one or several bins. In order to set an informative bin system, it is recommended to experimentally find a meaningful ratio upper level (for example 0.5). The chosen upper level should work over all cells presented in a studied image or image set. It is worth noting that decreasing or increasing the number of bins may result in under or over representation of cell classes respectively. In the liver toxicology example, hepatocytes having a low fat content may be assigned to a blue bin, cells having a moderate fat content may be assigned to a yellow bin, and cells having a high fat content may be colored red. However, to achieve a smooth color transformation between the three representative colors, for example, r > multiple bins (representing shades between the colors blue-to-yellow, and yellow-to-red) for cells having a particular fat content may be used. For example, using 10 bins: bin 1 = 0 fat content; bin 2 = 12.5% fat content; bin 3 = 25% fat content; bin 4 = 37.5% fat content; bin 5 = 50% fat content; bin 6 = 62.5% fat content; bin 7 = 75% fat content; bin 8 = 87.5% fat content; bin 9 = 95% fat content; and bin 10 = 100% fat content. Bin 1 may represent the blue color, bin 5 yellow and bin 9 red. Thus, bins 2-4 may be varying shades between blue and yellow and bins 6-8 may be varying shades between yellow and red. Alternatively, bins 1-3 may be blue, bins 4-7 may be yellow, and bins 8-10 red. Figs. 8A-8C represents a tissue image, a segmented image, and a PTM for a specimen of normal liver tissue (bin legend also included) , and Figs. 9A-9C represent the corresponding figures for abnormal liver tissue. As shown, the PTM for the normal tissue includes a low fat content (generally between 0.2 and 0.5), while the fat content is quickly determined to be higher than that of the normal tissue because of the increase in the number of hepatocytes colored yellow. After the PTM is created, the PTM statistics (e.g., hepatocyte fat content) may be loaded into a database. For example, the relative areas occupied by each cell class ~ percentage of cells with low object content, with moderate content etc. Other characteristics may be assigned to created cell classes.
Prostate Cancer Analysis A PTM may be generated for other histopathological tissue types or quantifications for prostate cancer. In prostate cancer, the granularity unit may comprise a tissue core (tile) gland unit, or to an entire tissue section. A prostate tissue core (tile) gland unit is a key structure for accessing the distortion of the normal prostate architecture (i.e., the degree of malignancy). A gland unit includes lumen, epithelial cells and cytoplasm objects. The relative lumen area with respect to tissue core area may serve as the quantification object for a PTM. This ratio characterizes cancer development in the tissue core: the more aggressive a cancer, the more gland units with small relative area values exist. A PTM may also be created to determine Gleason grade on an entire tissue section. The tissue section is partitioned on uniform gland units, and assigned, a Gleason grade. The Gleason grade is an integer number from 1 to 5, characterizing cancer aggressiveness. For example, five (5) bins may be established, each corresponding to a particular Gleason grade. Thereafter, each gland unit is matched with a bin, and the pixels in the tissue image corresponding to a respective gland unit are then colorized according to the color of the respective bin. The PTM is then generated and output to a user. Other Applications of PDMs The following is a list of cancers in which embodiments of the present invention may aid in determining the pathology thereof. Squamous cell Lung Carcinoma. Cytoplasm, distinct cell borders and/or interceller bridges may be quantified and used to generate a PTM to diagnosing or determining an extent of squamous cell carcinoma. Poorly differentiated carcinomas have a worse prognosis and they are more aggressive than the well differentiated. A well- differentiated carcinoma resemble a normal lung architecture. Fig. 10 illustrates this cancer, showing nests of polygonal cells with pink cytoplasm and distinct cell borders. The nuclei are hyperchromatic and angular. Bronchioloalveolar Lung carcinoma. Columnar cells may be quantified to determine diagnosis and/or extent of bronchioloalveolar carcinoma. Cancerous columnar cells are well-differentiated and can be seen in Fig. 11. Small cell Anaplastic (oat cell). Cells having minimal cytoplasm may be quantified to produce a PTM to determine a diagnosis and extent of small cell anaplastic (oat cell). As shown in Fig. 12, small cell anaplastic is evident from the small dark blue cells with minimal cytoplasm are packed together in sheets, which typify oat cell disease. Colon Cancer. Malignant glandular neoplasia, which are tubular structures (Fig. 13), with necrosis and hyperchromasia, may be quantified to produce.a PTM to determine colon cancer. In addition, the cancer may be diagnosed by reviewing cancerous goblet cells (Fig. 14) may also be quantified to produce a PTM for colon cancer.
Bladder cancer. Muscle invasiveness of transitional cell carcinomas may be quantified and used to produce a PTM, to determine bladder cancer. Fig. 15 illustrates a pathological staging of bladder cancer based on invasiveness. Quantification of papillary projections (Fig. 16 illustrating cancerous projections) for determining transitional cell carcinoma of the urothelium may also be used to produce a PTM. As shown in Fig. 17, neoplastic cells have uniform oval nuclei, abundant cytoplasm, and are arranged in ribbons of tissue supported by delicate vascular cores or "stalks". Fig. 18, a photomicrograph of "carcinoma in situ" in the bladder. The epithelial cells on the left have malignant cytologic objects including very large, irregularly shaped and darkly staining nuclei, which contrasts with the normal appearance of the urothelial cells on the right. Accordingly, the foregoing may be quantified to produce a PTM.
Pathology Models A PTM and/or basic object measurements may form a feature vector for biostatistical modeling, where advanced statistical models are used in order to classify the tissue image as being normal, abnormal, diseased and the like. Specifically, a neural network or SVR machine may be trained to make a comparison of a PTM to a PTM (or statistics thereof) from profiled data. To that end, one embodiment of the invention provides a method of automated H&E image analysis for liver toxicology and other medical areas.
Database The present invention is also directed to a robust database that is based upon input parameters that may be uniformly investigated and extracted from different studies. Specifically, embodiments of the invention include a database that allows input and retrieval of data and images needed to compare studies taking place at different times, with different protocols, and with measurements made by different systems. Accordingly, the database may preserve the utility of the stored information through continued lossless combination and comparability with subsequently acquired information and the accessibility of the stored images for automated re-analysis. Images and data may be stored together or separately (preferred). The data may be kept in spreadsheets, or through fields of a relation database. If the images and data are separately stored, the images and data can be merged using hyperlinks (for example). From a practical standpoint, a more robust database that manages the input and retrieval of data and images may be used to compare studies taking place at different times, with different protocols, and with measurements made by different systems. The database may include sufficient and accurate information to enable the user to normalize the results to make meaningful comparison between studies. EXAMPLES
Example 1 - Liver Tissue Image Segmentation - Portal Tract
Bile Duct Analysis of Bile Duct demonstrates that it is a tissue structure consisting of lumen (white area on the original image fragment Fig. 4A; colored yellow on the segmented image Fig. 4B) lined by simple cuboidal or columnar epithelium (epithelial nuclei painted by blue color on the segmented image).
Vessels Hepatic Vein Analysis of the Hepatic Vein (see Figs. 5 A original image; Fig. 5B segmented image) which is the largest diameter vessel, reveals it to be another tissue structure consisting of lumen (large white area on the original image fragment colored light grey on the segmented image) which has the typical, thin- walled structure relative to the diameter of the lumen and irregular outline of all veins (colored aquamarine on the segmented image).
Hepatic Artery and arterioles The smaller diameter, thick- walled vessels with the typical structure of arterioles and arteries are branches of the Hepatic Artery which supplies oxygenated blood to the liver. The Hepatic Artery is composed of a large white area (lumen) surrounded by a smooth muscle fibers wall that his thickness approaches the diameter of the lumen. Occasionally red blood cells can be found within the lumen area. See Fig. 6A original image and Fig. 6B segmented image of Hepatic artery.
Lymphatics Another type of vessel, lymphatics, are also present in the portal tracts, but since their walls are delicate and often collapsed they are not readily seen. Hepatocytes Hepatocytes are large, polyhedral cells which have a variable cytoplasmic appearance depending on the nutritional and health status of the body. In well-nourished individuals, hepatocytes store significant quantities of glycogen and process large quantities of lipid. Both of these metabolites are partially removed during routine histological preparation thereby leaving irregular, unstained areas within the cytoplasm, (vacuoles). The remaining cytoplasm is strongly eosinophilic due to a high content of organelles. The nuclei of hepatocytes are relatively large with peripherally dispersed chromatin and prominent nucleoli. The nuclei, however, vary greatly in size. Occasional binucleate cells are seen in section although up to 25% of all hepatocytes are bionucleate. The arrangement of hepatocytes within the liver parenchyma is distinct. The hepatocytes form flat, anastomosing plates usually one cell thick between which sinusoid course. Analysis of hepatocytes (Figs 7A-7B; 8A-8B) reveals cells formed by hepatic nuclei (dark ring on the pink background) and surrounding cytoplasm. The cell boundaries often go along sinusoids. A healthy cell may have an insignificant amount of fat. The more fat present in the cell, the more abnormal the cell is, and the liver is diagnosed as fatty liver. A hepatic nuclei can be completely replaced by excess fat deposit within the liver cell. Figs. 8A-8C depict images of normal hepatocytes and Figs. 9A-9C are images of abnormal hepatocytes containing excess fat. The resulting PTM for the present example is presented in Figs 8C (normal fat content) and 9C (abnormal fat content). The color changes from blue (low fat content) through yellow (moderate fat content) to red (high fat content). As is clear, there is a significant amount of fat (light round different size objects) around the hepatic nuclei in the abnormal hepatocytes.
Example 2 This study was undertaken to demonstrate neural network and linear discriminant analysis (LDA) modeling capabilities of the present invention. Specifically, the study involved the acquisition and analysis of sections of rat liver with the overall objective being to classify the sections as normal or abnormal. Being able to automate this process while simultaneously achieving a high-level of classification accuracy allows for the creation of a high-throughput platform used to objectively screen for toxicities in pre- clinical studies. The study was divided into two phases. The initial phase used a set of 100 rat liver sections as a training set; 80 normal liver sections and 20 abnormal. The image analysis process was then applied to an unlabeled set of 100 rat liver sections in the second phase of the study in which the statistical models designed in the training phase were tested.
Pathology Both the training and test set of rat liver sections were H&E-stained slides. Each set consisted of 100 slides. The training set of slides contained 80 normal liver sections and 20 abnormal liver sections. The testing set contained no information as to whether the sections were considered normal or abnormal. Images were taken by a pathologist, using the Spot Insight QE digital camera mounted on the Nikon Eclipse E400 microscope with the use of the Advance Spot software. The working objective was a 20X Plan Apo, and 24bits/pixel color images were taken and stored in TIF uncompressed file format with size 1200x1600 pixels. The resolution was 2744 pixels/mm.
Tissue Image Processing The tissue image processing system provides necessary information for the objective classification of an H&E stained liver section as being normal or abnormal, where basic and composite histopathological objects in the tissue image were found and quantified. The image segmentation was conducted by partitioning a tissue image into non- overlapping, constituent connected regions and assigning a meaningful label to each region. The labels correspond to histopathological objects of the liver tissue. The image analysis method defines quantitative characteristics (measurements) for all objects detected on the segmented tissue image. The implemented image processing system consists of three main components: preprocessing, image segmentation and object measurements.
Basic and Composite Moφhological Objects The following basic pathological objects were selected: nuclei, sinusoids, fat, fat vacuoles, blood vessels: hepatic veins and arteries, cytoplasm, red-blood cells. The nuclei were further classified as hepatic, kupffer, epithelial and inflammatory cells. The considered morphological structures which were composed of the basic objects were: hepatocytes with fat and fat vacuoles, hepatocytes with hepatic nuclei, hepatocytes. The hepatocytes are moφhological tissue elements formed by hepatic nuclei and attached cytoplasm.
Preprocessing Color variations from image to image are the most common drawback of the H&E staining procedure. The spectral properties of the same objects also vary from image to image which affects the accuracy and robustness of segmentation. A color normalization technique based on histogram matching was used in order to address the color variation problem. An image having good staining quality and representative color was chosen as a reference. The color histograms of the remaining images were transformed to match the RGB histograms of the reference image.
Image Segmentation The tissue images are 24 bits/pixel color images stored in TIF file format with size 1200x1600 pixels. In the image processing system, each image is represented by six layers: three original RGB layers and three normalized layers. Basic pathological objects form classes; segmented objects (e.g. nuclei) are the instances of a class. Besides the basic classes special auxiliary classes were created. Conceptually the image processing system was designed as a multilevel system. Each level is a virtual image plane with class instances corresponding to a certain processing stage. Level 1 is the starting level where the whole image is partitioned into non- overlapping, unclassified regions (image objects). The image objects may be merged by some criteria on the upper levels forming the super-objects with respect to objects on the lower level (sub-objects). The image objects may be networked so that each object is associated to its neighborhood, its super-object and its sub-objects. All sequential processing is about proper management (classification and merging) of the obtained image objects. At the beginning, all image objects were classified into three auxiliary classes "nuclei" (dark), "white space" (light) objects and "unclassified" objects respectively.
Nuclei Segmentation The nuclei segmentation started from the second level. Three color normalized layers were used to classify image objects as "nuclei" and "unclassified" objects. The pathologically valid nuclei (instances of the class "Nuclei") were formed from the "nuclei" objects with the use of growing (adding the neighboring "unclassified" objects to a nucleus) and fusion (merging of same class objects into one object), and moφhological opening/closing algorithms were applied in order to improve nuclei segmentation.
White Space Segmentation The segmentation results from the second level were carried over to the third level using a level copy operation. On that level, all "unclassified" objects were classified to "white space" and "unclassified" (remaining) objects, respectively. Image object brightness was used as the primary object for classification. A set of complications prevented the system from using brightness based threshold as ultimate classifier of "white space" objects: "white space" objects are not always "light", low contrast images produces false "white space" objects, and "white space" area on the tissue often filled with blood and other fluids. In order to overcome the above outlined problems, actual "white space" objects were composed with the use of the mentioned growing, fusion and moφhological opening algorithms. The obtained "white space" objects were classified to (Levels 3 and 4): red blood cells, sinusoids: elongated, contain red blood cells and within certain distance from kupffer cells, fat vacuoles: round, small and relatively dark "white space" objects, vessels: relatively big "white space" objects with smooth shape, and fat: remaining "white space" objects. All the remaining "unclassified" image objects in Level 4 are classified as instances of "cytoplasm". After fusion they form the cytoplasm area.
Moφhological Object Segmentation The moφhological object segmentation is an example of a high stage of the tissue image processing. The detected histopathological basic objects such as hepatic nuclei and cytoplasm were used to form the hepatocytes. The hepatocytes formation algorithm may be outlined as follows. The hepatic nuclei were used as seeds. A region growing algorithm was applied in order to grow hepatocytes from the cytoplasm, fat and fat vacuoles class objects. The cell continued growing until the following conditions were met: a) two growing hepatic cells touch each other; and b) the hepatic cell achieved a predefined size (measured as the distance from the seed). In the case when two or more hepatic nuclei were located close together, a modified growing algorithm kept the hepatocytes isolated.
Object Measurements The object measurement is the final stage of tissue image processing. The measurements are quantifications of all segmented histopathological basic objects and structures.
Histopathological Object Quantification For each segmented class of the basic histopathological objects of the tissue image, the following data were output: number of the objects (n/a for cytoplasm area), class area relative to the total tissue area (%), individual object statistics: min/max area, average and standard deviation of the area values over the image. Moφhological Object quantification The unique phase of the tissue image processing is the quantification of moφhological objects. The analysis of hepatocytes based on the fat and hepatic nuclei contents are examples of such quantification. The ratio of the fat (hepatic nuclei) area of a single hepatocyte to the hepatocyte total area is determined. The ratio constitutes the fat (hepatic nuclei) content. It serves as a measurement of cell health: normal vs. abnormal. The theoretical fat and hepatic nuclei contents range from 0 (a cell free of fat or hepatic nuclei) to 1 (a cell replaced by fat or hepatic nuclei). This range is divided into a number of bins. Coloring each cell based on a color associated with its bin range produces the steatotic PTM. The color changes from blue (a low content) through yellow (a moderate content) to red (a high content). The fat PTM was processed on the Level 5 objects and nuclei density PTM on the Level 6 objects. All hepatocytes were classified into ten classes: "Fat Ratio" 1 - 10 and "Hepatic Nuclei Ratio" 1 - 10. The PDMs, hepatocytes area and basic object measurements form a feature vector for biostatistical modeling.
Segmentation Accuracy The global segmentation accuracy for all objects, as measured by a pathologist' s assessment, was 80% - 90%.
The preferred embodiments described herein are provided to enable any person skilled in the art to make and use the present invention. The various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without the use of the inventive faculty. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the claims. The automation of object extraction in embodiments of the present invention create a high throughput capability that enables analysis of serial sections for more accurate measurements. Measurement results may be input into a relational database where they can be statistically analyzed and compared across studies. As part of the integrated process, results may also be imprinted on the images themselves to facilitate auditing of the results. The analysis may be fast, repeatable and accurate while allowing the pathologist to control the measurement process. The present application claims benefit of U.S. provisional patent application no. 60/520,815, filed November 17, 2004, the entire disclosure of which is herein incoφorated by reference in its entirety.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|WO1996009594A1 *||6 Sep 1995||28 Mar 1996||Neopath, Inc.||Apparatus for automated identification of thick cell groupings on a biological specimen|
|US4097845 *||18 Aug 1977||27 Jun 1978||Rush-Presbyterian-St. Luke's Medical Center||Method of and an apparatus for automatic classification of red blood cells|
|US5016283 *||17 Nov 1987||14 May 1991||Cell Analysis Systems, Inc.||Methods and apparatus for immunoploidy analysis|
|US5526258 *||23 Aug 1995||11 Jun 1996||Cell Analysis System, Inc.||Method and apparatus for automated analysis of biological specimens|
|US6137899 *||22 Jul 1998||24 Oct 2000||Tri Path Imaging, Inc.||Apparatus for the identification of free-lying cells|
|1||*||EGMONT-PETERSEN M ET AL: "Image processing with neural networks-a review" PATTERN RECOGNITION, ELSEVIER, KIDLINGTON, GB, vol. 35, no. 10, October 2002 (2002-10), pages 2279-2301, XP004366785 ISSN: 0031-3203|
|2||*||SCHOELKOPF B ET AL: "COMPARING SUPPORT VECTOR MACHINES WITH GAUSSIAN KERNELS TO RADIAL BASIS FUNCTION CLASSIFIERS" IEEE TRANSACTIONS ON SIGNAL PROCESSING, IEEE SERVICE CENTER, NEW YORK, NY, US, vol. 45, no. 11, November 1997 (1997-11), pages 2758-2765, XP001133714 ISSN: 1053-587X|
|3||*||YEH W-C ET AL: "Liver fibrosis grade classification with B-mode ultrasound" ULTRASOUND IN MEDICINE AND BIOLOGY, NEW YORK, NY, US, vol. 29, no. 9, September 2003 (2003-09), pages 1229-1235, XP004463701 ISSN: 0301-5629|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|WO2013042018A1 *||13 Sep 2012||28 Mar 2013||Koninklijke Philips Electronics N.V.||Adapting an x-ray slave image to an x-ray master image|
|WO2013167139A1 *||10 May 2013||14 Nov 2013||Dako Denmark A/S||Method and apparatus for image scoring and analysis|
|CN102369530A *||21 May 2010||7 Mar 2012||皇家飞利浦电子股份有限公司||Method and device for side-effect prognosis and monitoring|
|EP1953662A1 *||30 Jan 2008||6 Aug 2008||Boehringer Mannheim Gmbh||Molecular histology|
|US8114615||17 May 2007||14 Feb 2012||Cernostics, Inc.||Method for automated tissue analysis|
|US8597899||24 Aug 2012||3 Dec 2013||Cernostics, Inc.||Method for automated tissue analysis|
|US9412333||13 Sep 2012||9 Aug 2016||Koninklijke Philips N.V.||Adapting an X-ray slave image to an X-ray master image|
|International Classification||G06T7/00, A61B5/05, G06T5/00, G06K9/00, G06T7/60|
|Cooperative Classification||G06T7/187, G06T7/155, G06T2207/10056, G06T7/11, G06T2207/30061, G06K9/00127, G06T2207/30056, G06T7/0012, G06T7/62, G06T2207/20036, G06T2207/30024|
|European Classification||G06T7/00B2, G06T7/00S1, G06T7/00S6, G06T7/60A, G06K9/00B|
|2 Jun 2005||AK||Designated states|
Kind code of ref document: A2
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
|2 Jun 2005||AL||Designated countries for regional patents|
Kind code of ref document: A2
Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
|27 Jul 2005||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|18 May 2006||NENP||Non-entry into the national phase in:|
Ref country code: DE
|18 May 2006||WWW||Wipo information: withdrawn in national office|
Country of ref document: DE
|27 Dec 2006||122||Ep: pct application non-entry in european phase|